Patents by Inventor Isabelle Catherine Batxelli
Isabelle Catherine Batxelli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220205039Abstract: The application concerns means for determining the stage of hepatic tissue damage, in particular the hepatic fibrosis score of subjects infected with one or more hepatitis viruses. In particular, the means of the invention involve measuring the levels of expression of selected genes, said selected genes being: SPP1, and at least one gene from among A2M and VIM, and at least one gene from among IL8, CXCL10 and ENG, and optionally, at least one gene from among the list of the following sixteen genes: IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, MMP7, S100A4, TIMP1, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1.Type: ApplicationFiled: December 28, 2021Publication date: June 30, 2022Inventors: BÉNÉDICTE WATELET, TARIK ASSELAH, IVAN BIECHE, ISABELLE CATHERINE BATXELLI, NATHALIE JULLIAN, MICHEL VIDAUD, PATRICK MARCELLIN, DANIEL LAUNE, MOHAMMAD AFSHAR, EVE LAURE MATHIEU
-
Publication number: 20210239713Abstract: The application relates to hepatic fibrosis, specifically to hepatic fibrosis that may appear in a patient infected with one or more hepatitis viruses and/or who is suffering from hepatitis, specifically chronic hepatitis. The application provides methods and means for determining the stage (or degree) of hepatic fibrosis of such a patient. Specifically, the methods and means of the application make it possible to determine whether or not the stage (or degree) of hepatic fibrosis of the patient has exceeded the stage of light fibrosis. The methods and means of the invention use a combination of biomarkers such as, in particular, the CXCL10 protein and hyaluronic acid (HA).Type: ApplicationFiled: April 9, 2021Publication date: August 5, 2021Inventors: NADINE LAMBERT, BENEDICTE WATELET, ISABELLE CATHERINE BATXELLI, TARIK ASSELAH
-
Patent number: 10976324Abstract: The application relates to hepatic fibrosis, specifically to hepatic fibrosis that may appear in a patient infected with one or more hepatitis viruses and/or who is suffering from hepatitis, specifically chronic hepatitis. The application provides methods and means for determining the stage (or degree) of hepatic fibrosis of such a patient. Specifically, the methods and means of the application make it possible to determine whether or not the stage (or degree) of hepatic fibrosis of the patient has exceeded the stage of light fibrosis. The methods and means of the invention use a combination of biomarkers such as, in particular, the CXCL10 protein and hyaluronic acid (HA).Type: GrantFiled: June 9, 2015Date of Patent: April 13, 2021Inventors: Nadine Lambert, Benedicte Watelet, Isabelle Catherine Batxelli, Tarik Asselah
-
Publication number: 20200056235Abstract: The application concerns means for determining the stage of hepatic tissue damage, in particular the hepatic fibrosis score of subjects infected with one or more hepatitis viruses. In particular, the means of the invention involve measuring the levels of expression of selected genes, said selected genes being: SPP1, and at least one gene from among A2M and VIM, and at least one gene from among IL8, CXCL10 and ENG, and optionally, at least one gene from among the list of the following sixteen genes: IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, MMP7, S100A4, TIMP1, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1.Type: ApplicationFiled: August 28, 2019Publication date: February 20, 2020Inventors: BÉNÉDICTE WATELET, TARIK ASSELAH, IVAN BIECHE, ISABELLE CATHERINE BATXELLI, NATHALIE JULLIAN, MICHEL VIDAUD, PATRICK MARCELLIN, DANIEL LAUNE, MOHAMMAD AFSHAR, EVE LAURE MATHIEU
-
Patent number: 10435744Abstract: The application concerns means for determining the stage of hepatic tissue damage, in particular the hepatic fibrosis score of subjects infected with one or more hepatitis viruses. In particular, the means of the invention involve measuring the levels of expression of selected genes, said selected genes being: SPP1, and at least one gene from among A2M and VIM, and at least one gene from among IL8, CXCL10 and ENG, and optionally, at least one gene from among the list of the following sixteen genes: IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, MMP7, S100A4, TIMP1, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1.Type: GrantFiled: April 17, 2017Date of Patent: October 8, 2019Assignees: BIO-RAD EUROPE GMBH, ARIANA PHARMACEUTICALS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Bénédicte Watelet, Tarik Asselah, Ivan Bieche, Isabelle Catherine Batxelli, Nathalie Jullian, Michel Vidaud, Patrick Marcellin, Daniel Laune, Mohammad Afshar, Eve Laure Mathieu
-
Patent number: 9879320Abstract: The application concerns means for predicting whether a subject infected with one or more HCVs has a high probability of responding to an anti-HCV treatment which will comprise the administration of interferon and of ribavirin or whether, in contrast, that subject has a high probability of not responding to that anti-HCV treatment. The means of the invention in particular involve assaying the levels of expression of selected genes, said selected genes being: at least one gene from among MBL2, LGALS3BP and IL8, and at least one gene from among G1P2, CCL21 and CXCL10, and optionally, at least one gene from among AFP, CRP, CXCL11, CXCL6, CXCL9, FGF7, MDK, MMP2, SFN, TGFB2 and VEGFD.Type: GrantFiled: February 9, 2012Date of Patent: January 30, 2018Inventors: Ivan Bieche, Bénédicte Watelet, Tarik Asselah, Isabelle Catherine Batxelli, Eve Laure Mathieu, Nathalie Jullian, Michel Vidaud, Patrick Marcellin, Mohammad Afshar
-
Publication number: 20170283871Abstract: The application concerns means for determining the stage of hepatic tissue damage, in particular the hepatic fibrosis score of subjects infected with one or more hepatitis viruses. In particular, the means of the invention involve measuring the levels of expression of selected genes, said selected genes being: SPP1, and at least one gene from among A2M and VIM, and at least one gene from among IL8, CXCL10 and ENG, and optionally, at least one gene from among the list of the following sixteen genes: IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, MMP7, S100A4, TIMP1, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1.Type: ApplicationFiled: April 17, 2017Publication date: October 5, 2017Inventors: BÉNÉDICTE WATELET, TARIK ASSELAH, IVAN BIECHE, ISABELLE CATHERINE BATXELLI, NATHALIE JULLIAN, MICHEL VIDAUD, PATRICK MARCELLIN, DANIEL LAUNE, MOHAMMAD AFSHAR, EVE LAURE MATHIEU
-
Publication number: 20170160289Abstract: The application relates to hepatic fibrosis, specifically to hepatic fibrosis that may appear in a patient infected with one or more hepatitis viruses and/or who is suffering from hepatitis, specifically chronic hepatitis. The application provides methods and means for determining the stage (or degree) of hepatic fibrosis of such a patient. Specifically, the methods and means of the application make it possible to determine whether or not the stage (or degree) of hepatic fibrosis of the patient has exceeded the stage of light fibrosis. The methods and means of the invention use a combination of biomarkers such as, in particular, the CXCL10 protein and hyaluronic acid (HA).Type: ApplicationFiled: June 9, 2015Publication date: June 8, 2017Applicant: BIO-RAD INNOVATIONSInventors: NADINE LAMBERT, BENEDICTE WATELET, ISABELLE CATHERINE BATXELLI, TARIK ASSELAH
-
Patent number: 9624541Abstract: The application concerns means for determining the stage of hepatic tissue damage, in particular the hepatic fibrosis score of subjects infected with one or more hepatitis viruses. In particular, the means of the invention involve measuring the levels of expression of selected genes, said selected genes being: SPP1, and at least one gene from among A2M and VIM, and at least one gene from among IL8, CXCL10 and ENG, and optionally, at least one gene from among the list of the following sixteen genes: IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, MMP7, S100A4, TIMP1, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1.Type: GrantFiled: February 9, 2012Date of Patent: April 18, 2017Assignees: BIO-RAD INNOVATIONS, ARIANA PHARMACEUTICALS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Bénédicte Watelet, Tarik Asselah, Ivan Bieche, Isabelle Catherine Batxelli, Nathalie Jullian, Michel Vidaud, Patrick Marcellin, Daniel Laune, Mohammad Afshar, Eve Laure Mathieu
-
Publication number: 20140223588Abstract: The application relates to a polypeptide, the amino acid sequence of which is the sequence of a sub-fragment of the C-terminal thioester-cleaved fragment of human alpha-2-macroglobulin (A2M), wherein the molecular weight of said polypeptide is of 36 to 44 kDa, and wherein the first N-terminal amino acid of said polypeptide is an amino acid, which, in the full length sequence of said human A2M, is at a position 1,098 or 1,085 or 1,084 or 1,083, and the last C-terminal amino acid of said polypeptide is an amino acid, which, in the full length sequence of said human A2M, is one of the last twenty C-terminal amino acids. This polypeptide is differently abundant depending on the stage of liver fibrosis. The application also relates to means deriving therefrom and to the application thereof, notably in the field of hepatitis.Type: ApplicationFiled: July 27, 2011Publication date: August 7, 2014Applicant: BIO-RAD INNOVATIONSInventors: Isabelle Catherine Batxelli, Bénédicte Watelet
-
Publication number: 20130323720Abstract: The application concerns means for determining the stage of hepatic tissue damage, in particular the hepatic fibrosis score of subjects infected with one or more hepatitis viruses. In particular, the means of the invention involve measuring the levels of expression of selected genes, said selected genes being: SPP1, and at least one gene from among A2M and VIM, and at least one gene from among IL8, CXCL10 and ENG, and optionally, at least one gene from among the list of the following sixteen genes: IL6ST, p14ARF, MMP9, ANGPT2, CXCL11, MMP2, MMP7, S100A4, TIMP1, CHI3L1, COL1A1, CXCL1, CXCL6, IHH, IRF9 and MMP1.Type: ApplicationFiled: February 9, 2012Publication date: December 5, 2013Applicant: BIO RAD INNOVATIONSInventors: Bénédicte Watelet, Tarik Asselah, Ivan Bieche, Isabelle Catherine Batxelli, Nathalie Jullian, Michel Vidaud, Patrick Marcellin, Daniel Laune, Mohammad Afshar, Eve Laure Mathieu
-
Publication number: 20130316332Abstract: The application concerns means for predicting whether a subject infected with one or more HCVs has a high probability of responding to an anti-HCV treatment which will comprise the administration of interferon and of ribavirin or whether, in contrast, that subject has a high probability of not responding to that anti-HCV treatment. The means of the invention in particular involve assaying the levels of expression of selected genes, said selected genes being: at least one gene from among MBL2, LGALS3BP and IL8, and at least one gene from among G1P2, CCL21 and CXCL10, and optionally, at least one gene from among AFP, CRP, CXCL11, CXCL6, CXCL9, FGF7, MDK, MMP2, SFN, TGFB2 and VEGFD.Type: ApplicationFiled: February 9, 2012Publication date: November 28, 2013Applicants: BIO-RAD INNOVATIONS, ARIANA PHARMACEUTICALS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALEInventors: Ivan Bieche, Bénédicte Watelet, Tarik Asselah, Isabelle Catherine Batxelli, Eve Laure Mathieu, Nathalie Jullian, Michel Vidaud, Patrick Marcellin, Mohammad Afshar